CMRX - Earnings call transcript Q4 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning ladies and gentlemen and welcome to the Chimerix Fourth Quarter and Year End 2021 Earnings Conference Call. I would now like to introduce your host for today's call Michelle LaSpaluto, Vice President of Strategic Planning and Investor Relations at Chimerix. Please proceed.

Michelle LaSpaluto

Thank you. Good morning everyone and welcome to the Chimerix fourth quarter and year end 2021 financial and operating results conference call. a on issued operating fourth we results. morning press our release quarter This

this our Andriole; Imipridones President Allen. release the can and our Medical press You access Chief Chief Melemed; in Officer, Officer, Sherman; me Financial Randall today's Officer, and Allen Executive Officer, website. on Josh Investors Science call Technology Chief are Mike Officer, and Business Mike Chief Chief With of section Lanier;

materially on today's we Securities statements. that and would those turn made other the Before uncertainties XXXX disclosure with other and and I the Mike the Sherman. from over our to filings of within in and to At to would Executive to Please Litigation Officer, subject I These and our like uncertainties. SEC risks and to of this differ for Private include you remind more call factors meaning forward-looking begin, the like Act referred time, and the these could to statements results are a risks actual complete factors. uncertainties call Chief forward-looking refer to statements the of President Reform cause risks

Mike Sherman

was for for Good and Michelle. everyone XXXX, pivotal us. the a thanks morning on Reflecting it company. Thanks certainly year joining

unique expected capital development. of our financial potential fund peers this to The market smallpox of human As strategically the protect substantial. our oncology to uncertainty. of somewhat particularly years. considerable to the has strategy TEMBEXA Public the of economic last source in increased health couple you around among TEMBEXA non-dilutive of a also know be threat and in awareness has critical to important need certainly population a consequences foundation access been the program long-term of satisfy, is built and outbreak. of The it's this our the company as provide is period valuable the to course, which capital threat drug This would will program from

With is approval attractive June perspective for value ages then of in robust resistance situation the in provided summary the crisis and this for and and to strategy BARDA The coming approval FDA FDA's indicated drug, request administered December, a all easily very on TEMBEXA's profile. the fruition. a with independent proposal a in this of

expected. the by was In BARDA's median over expected durability. of tumor and just of courses of drug and followed at a X.X those reduction As course more of the ONCXXX signing procurement treatment contract We data review. trigger Initial XX% treatment of achieved reported this particular responses remain important we'll treatment. negotiation TEMBEXA Oncoceutics, outcome cover brought national quantities negotiation started approval called which XXXX we report most a are The to for contract. the of the as been for months stockpile in data post-marketing strategic during people able And glioma. months to after was KXXM-mutant HX the confirm initial some we response the the data request organization we to in a least as an and had of order to rigorous it up were that acquisition well outstanding had well-positioned glioma, as million to a shipment oncology additional first it elements will as pipeline confirmed. of the which execution process, quality of of We pricing been a an poised XX than and on of not concludes. response for with at promising support the although ahead product And even central Compelling independent regulatory of year, stronger financially revealed the for the of of response a eight blinded of commitments. include already were durable through start the upon set the The median assets.

steroid many apparent always improvement internal when progression sobering continue the to of the confirmation this Importantly, treatment longer that in status was but receive survival. lack profile compelling the across of and of that associated the evidence consistency is mattered safety these of options it probably has use these reassuring The responses with ONCXXX the patients for most as data a drug they patients. the It's after fact even is for kind reduction a were of endpoints. performance also

used the initiated as discovered, also and standards plan XX-patient of Because to data related which this observe FDA, recognized this was more meet be KXXM to WHO We're potential in this under and as population. were our initiate During patients the well the collaborated plan in running XXXX, drug want from same to course, We work discuss during what is natural we been fact case, that sites treated In and potential held meantime. to for for also randomized field with and from the as We ONCXXX efficacy study. submitted HX in for in of disease the application this on than FDA's FDA a the second with a of trial the a XXX review relatively new of to up half We've these data a frankly, CMC the activities, of work FDA FDA review not the deliverables who actively that, rare a collection This We've ONCXXX. executing the patients. data the protocol, to HX mutation on year newly this to gathering with of includes KXXM engaged safety now preparations have validation we number design. it patients, analysis. already trial a this clinpharm we're care for with in important criteria the responses frontline setting. is have and of meetings the was those NDA. history post-radiation and submit in current the

You treatment clinical the through a can about be data data trials awareness is patients access. high, which size months, of or information large expanded ONCXXX collected next this the more this in ONCXXX retrospective been set as with has won't Keep from We'll sought know study, and many collect imagine mind set will in data previously treated a and verified. couple of of as that is that patients. out

ONCXXX independent analysis, review same response data the central analysis. for For efficacy the this we to we to plan subject process, the use blinded

be these to midyear. by streams expect each our regulatory in far with provide on ongoing guidance lines consultation along work We to and the time FDA enough of

competitive III Enrollment of proceeded shortages this due frontline program, AML. the ongoing for population. subjects study COVID-XX, Phase staffing and more this hospital trial in slowly than Now, let has me to in turn enrolling to expected our DSTAT the environment the related DASH to

to we to call like As Dr. anticipated a endpoint a development. are has help options we number and over of and particular serve a year-end developments One that, supporting to With the that, surrogate to Lanier currently may momentum, don't to DSTATs result, in tailwind materialized to patients XX with the discuss complete expect reviewing AML CMXXXX. this recent space I'd in hand accelerate by as potential MRD our longer-term development. of enrollment the accelerate first in

on to while our legacy that, previously potential antiviral heard with library. expected me we our shifted focus be mention value we has You've that, sitting oncology, may

identify on have focus been value against value been molecules this without to begins that world viruses, families Carolina the pandemic entire collaboration us potential library highlighted. really preparedness of University in of of helping the other by projects. phenomenal has North This focus that on identifying potential losing As with has

the results project progressed very As this this became and saw highly work the of collaborators subsequent quickly. initial of highest credible priority their team experiments, has

more one assets learned from share this Let library. what the me let stop mature of and there, Randall we've on Randall?

Randall Lanier

agents recently one This Hill. animal READDI UNC promising of in some actively profiles improved in including We've resistance at deep expertise address to efficacy variance of preclinical and year. Carolina which generated done Mike. explore antiviral rapidly Chapel the of and said development drugs. SARS-CoV-X. Mike emergency an novel data collaboration for last of been that late emerging and in Thanks, to to authorization antiviral, use the with pandemic, continuing with this current of the as received North with anticipated have develop the They our model have involved University initiative COVID-XX was SARS-CoV-X READDI, efforts very activity other drug in established proprietary therapies area, are

other attractive, needed collaboration because through GLP has indication. for it them volunteer enabled myriad of involves of particularly animal in and up favorable a included developed and start chemical many of Phase SARS-CoV-X. derisks the study Our work was This volunteer study that our is of this with another several CMXXXX was from a nucleoside a safety. I well study. CMXXXX all safety, of key to buildup trials. very is for has very cytotoxic, manufacturing X.X grams The CMXXXX to drug and important healthy It's common previously standard to against studies in not healthy often development, GMP in most Phase profile early a activity high and tolerated human completed or the genotoxic, studies myotoxic library the not pitfalls levels which humans. analog safety I

of initiated reducing placebo. of activity SARS-CoV-X lungs For CMXXXX a XX.XX% very starting times eight COVID studies of the also at associated into loss or both reduced at or in And post reduced or the model therapeutic aerosolized various humans. administered COVID. CMXXXX dose weight completed hours day The well-studied day these can Treatment to minute. this significantly logs infection in reasons the to one Administration rather studies protected human to viral mouse titers of think decreasing the for mouse more program while The CMXXXX to treatment prior a for and from prior the four. leads weight to in with lungs infection pathology quickly. loss both lung proof-of-concept safety. with aerosolized at placebo. symptoms equivalent moved disease delivery we by disease, mouse describe or infection hours and lung four efficacy viral exposure. CMXXXX in eight enables prevented In model to one infection administration clinical of and And study and and explore I'll at of a is eight XX the efficacy significantly than the inhaled clinical potential hours the a SARS-CoV-X be a the data improves compared model titer efficacy. on roughly in and average placebo compelling day non-clinical the minimizing about progression was to X.X this in prophylactic mice to infection systemic direct Prophylactic relative model, CMXXXX versus demonstrated time

by lungs example infection of the titer or hours initiated an XX%. more as the X.X lung CMXXXX logs XX than amount than viral post Just SARS-CoV-X of more average reduced in

estimate with range fall in modeling could efficacious dry portable translation contemporary target the the predicts methods within Importantly, the clinical humans commonly that to or be doses delivered a of doses, doses should mice systems nebulizers used inhalers. like battery-powered powder in to

less variant currently to a excellent and Additional simple other compare assess humans. for have and for efficacy planned are studies model animal frequent to anti-virals. evaluate safety to or excellent in drive all mechanism potentially we doses and life combination administration and point virus-specific GMP the at clean efficacy the this other system in to prophylactic are profile that short with to broad proof-of-concept action, ready signs enough efficacy kilograms a path a model. lower proven underway of anti-viral Briefly coverage, in the with of patent use development, Furthermore, looks in

to we this procurement antiviral BARDA very library with CMXXXX evaluate with on looks the efficiently promising. TEMBEXA advancement and READDI collaboration our of our oncology towards While progress a and us agreement focus allowed pipeline

at with Conference And upcoming greater call where an have We turn that, Mike in month Research this presentation the in will this later the discuss I'll oral Antiviral over on to data late-breaker Seattle International Andriole. detail.

Mike Andriole

we press with full everyone. Thanks Starting related our the to for and acquisition capital issued sheet fund payable to we today containing year Randall, fourth release and end note balance good paid morning, our of In $XX January of million XXXX. we the January, Oncoceutics, had the December operations. quarter Earlier in approximately in at a XXXX. XXXX, of results a $XX million financial

Also Bank. EU Importantly not month $XX transaction million any with entered we credit a provide further or related that into last to of payments US owe financial we additional ONCXXX. Valley to line Silicon revolving flexibility, until approval do

on of We have be an use position as-needed facility We capital supplement to-date not have source drawn obligation as can utilized down that a on providing see and facility. do to the by tool alternative this it basis. our no an to financial

For this the could to facility example, to TEMBEXA between or in advance of orders. future credit shipment use an gap procurement we bridge of anticipated potentially BARDA

is be to forward occur the a commercial company the from a this As second sale pivotal ways Stockpile to financial certainly as quarter. expected and year XXXX, our to first in we of for we likely TEMBEXA look expect U.S. the National year during product to many Strategic perspective

As for TEMBEXA. X.X Mike have price, BARDA schedule their we proposal million RFP treatment response submitted our has courses delivery our details of which mentioned to of quantities and to

expect We sale revenue for a potential build oncology commercialization. enable fully to year in and the this potential to marketing the a and and ONCXXX pipeline sales years TEMBEXA U.S. from organization our of invest us in future

BARDA provide procurement confirmation As we precise will guidance. financial we have on a more of specifics the potential

back per fourth reported million the diluted company success to with of $X.XX quarter development to for the Oncoceutics million of compared primarily ONCXXX. XXXX, basic $X.X a included XXXX, for $X.XX And shareholders also per ONCXXX. overview, for RANO-HGG The loss Revenues $X.X period $X.X for achievement with XXXX. the to that to Turning of as payment $XX.X of same legacy quarter the success compared or a XXXX. the fourth share call milestone related in increased contract, by fourth BARDA net Research the turn fourth the research million in for decreased million of remarks. the million I'll Again completion expenses compared $X.X million million closing diluted for response quarter $XX.X to General period is the administrative of net a quarter $XX,XXX loss or to our $XX the million and XXXX and XXXX Mike in to for same compared with overall rate quarter relation development fourth for the the basic for for to increase million XX% with expenses same XXXX fourth and of the and of XXXX. period $XX of and to quarter Mike? share increased the of to operations, $XX.X this statement payment in in the XXXX. a

Mike Sherman

both an exciting the ONCXXX have and ahead certainly We Mike. Thanks in TEMBEXA programs. year with catalysts

during to year. In to a wasn't addition, questions. open look really on, this on now months the to that call to even With We building CMXXXX radar forward ready few momentum which ago. the Elizabeth, the

Operator

with Our first Jefferies. comes question Instructions] Maury Raycroft [Operator from

Maury Raycroft

the Hi going I good Congrats on process. and morning. progress thanks taking for the my questions. was to BARDA ask on

could PPOx what on the checking pricing that or Just versus on dialogue negotiations and of thoughts particularly there? guess finalize any couple And are BARDA, your how I confident put you can our are over finer next premium latest the the if points you [ph] with weeks timeline with occur months.

Mike Sherman

of I focused. to the have elements these that I think XX that, process. are negotiation see typically I play we would out don't know you processes much over insight into that XX more say days. pretty

about a feel it's of reviewers. that way and supported and the case who compelling And that making we that that BARDA course for end and our about for The the up delivery of small really and with mentioned, pricing or ensure really activities I rest former is work analytically. contract. schedule. a to being officials good reimbursement pricing We building really portion we're As can in proposal that is experts

soon feel know enough very was that. respond good response they to the I very how to we'll what So comprehensive about RFP. a But

Maury Raycroft

plan actively then internally as whether the your XXX, newer once grow you pursue to do Got pipeline, you XXX with means BARDA a or business XXX? the And focus contract saying are it. and the agent secured, you development is also will to

Mike Andriole

as it's investment continuously case Yeah, as growing opportunities. continues that having Mike organic the are do external We to the XXX pipeline for landscape well. the you said business Andriole. development require additional know evaluate of well Maury That ONCXXX programs and organically. been CMXXXX now may in grow

little continually say internal right it. opportunities we'll so but say and was before bar them And additional the external do to the But project than is we continuously bring I innovation the would a landscape. year year in or higher evaluate to it the now compare last external evaluate pipeline

Maury Raycroft

Got it.

I'll Okay queue. hop the back thanks for taking my in questions.

Mike Sherman

Thanks Maury.

Operator

question Quibria from Maxim next Our comes Naureen Group. with

Naureen Quibria

morning. on for good thanks and my the progress Congrats questions. Hi taking

contract guess also really on I BARDA it's very So question I the basic. and have a rather

forward Let's -- automatic? know say prices how moving Is that negotiated. first the negotiation, do what that's of it is or that guess I you ask? already are the part have What you want contract to triggers I procurement?

Mike Sherman

commitment negotiation Yeah that's of that shipment first quantity. the on essentially a part is

proposal Future negotiation those We implied So identified. along a triggering always pricing. an subject six within our they shipments schedule course those Those then the four those prepares research the are have are with manufacturing the that. quantity of that of of done go. timeframe. that -- part as course lot of over And years. the we've essentially that and to -- said shipments propose BARDA we've is for on And is to orders

that who other you reliably have pretty initial BARDA see predictably that executed over companies of contracts so space be would agreement the the they're can is the upfront. shipment part and essentially initial know You committed and and time that would and frame. operate in But

Naureen Quibria

very talk with can And to about regards filing, ONCXXX then Okay. various helpful. That's you components. the

needed that's filing for else history but study data? apart remains have natural from you think I regulatory what the

Mike Sherman

were treated defined the was criteria post far that select submission. to few a gathering XX patients. And And broader intended comprise goes what's with set benefit the drug Yeah, been data that isolate the that the efficacy will that said include activities. ONCXXX. to so really data than to the we've that work criteria streams used agent Recall also they support database year was have more potential beyond narrow. CMC is safety there having That XX the fact, by very been activities acquisition response to ongoing a single far there why and are much we're analysis. That for the in just last database broader clinpharm it than that's that support since patients be the data that FDA the safety narrow the

it's history of other that the a obviously those underway. among natural in field the alignment relatively treat element and this to mutation quite disease There's challenging mentioned bit a yet one new. is You is which

having data going -- the so supportive assumption And support and the application. of be is helpful that to to those

trial, gathering activity for and meet final as And NDA able well important on a think our to that patients. which both prognostic in outcomes which frankly alignment confirmatory in population are that it's running. into even we criteria as we're the helpful precisely going So accelerated you more have approval the piece a if same referenced an is, efficacy a important and drug then to identify patients up we as the trial potential want confirmatory demographic have of would future these in you're about will analysis predicting broader factors the a as which as development to be we secure are review to factors

And are on have design that so is FDA collaborating underway. the with dialogue that to alignment ensure we we and

Naureen Quibria

just you. just it trial about helpful. ask very I That's the to Thank actually that's you Well, you me. going was for answered it. confirmatory

Operator

question from with next Ed Our H.C. comes White Wainwright.

Ed White

taking question. Thanks morning. Good my for

the to maybe ONCXXX. continue on with So, just

what the are length just anything the tell time safety for Phase it size you submission. data the to randomized completion, cetera? submission? that. about with first-line perhaps of to the be trial. can any expectations of FDA, the running that for with know Thank X the study the And that concurrently you're I going us -- I'm et going you. study, you of Do your about You're curious placebo-controlled need to discuss

Mike Sherman

answer and the NDA Yes, of But -- who that Allen part do expect want I -- think, I'll from I we be submission. would add can the not safety or Josh required data to that trial as it. to that

profile of have that in seen we've particular of the submission of patients on the drug, and safety be will number be the discussions would that -- given FDA a identified with sufficient. population think patients this We we prior part that in

combination as determine I endpoints things future to think, this describing a would like and wait randomized, trial enroll which from size to Aside feedback would the from prudent the FDA then a be frontline on that time it to radiation line update. for with have

Josh Allen

I the appropriate the This already be evaluated just has would is of a just was pediatric moving dose in ONCXXX population monotherapy to add safety Josh. forward. found I the in that in would is as add this been for similar setting -- where used

leveraged is So safety prior already there experience. that that's from data

Ed White

And TEMBEXA the then Thanks. question.

other point? thoughts quarter. Are expect the thinking ongoing year How much from the the how You you're of getting get demand full about on second just out the see for you at in if to three the to had ready wanted manufacturing or you should outside we U.S. inquiries RFP quarters war it Could in deliver we to any U.S. and Just this the first the expect stockpiles? your the year? deliver spread And outside the Ukraine said with over you worth delivery? delivery in first be the wondering national should be then quarter, the now? you the right last prepared are and

Mike Andriole

stockpiling chime to really preparedness Ed never been There with Canada. in that along now. the pandemic is of second, we is, others countermeasures start start but stronger I'll it the explore get been that have in can part that Canada question and Canada. said have we case stockpiled We'll potential there as maybe has international than successfully other the have registration as opportunity work all and Mike for and been first in the in

certainly of of it over being essentially the those Europe could equivalent XXXX Health cycle and centralized after -- Response life near in we're is in and consideration the Europe in opportunities in a geopolitical but but continuing for topic, uncertainty United for the As country-specific Europe could We to to opportunity. going be explore be But mechanism be organized probably that that BARDA a of prioritize States. on and that. process European is opportunity we the this relates member see Eastern think probably to procurement to it's as don't Emergency a capitalized And there folks and term, the Authority HERA TEMBEXA. the the where yet likely

Mike Sherman

and of And in the want we ship the we to your BARDA, as $X.X of they indeed a question second are and prepared one-fifth that roughly part question, much position with whether – have take pricing million. indeed of associated on to how to away right The full remains that that.

So that will be negotiation. one of the that's first key of part sort of the terms

Ed White

Okay. and Thanks just reviewed thinking Mike. timing on I'm We And the question last see and to XX. initial data again. should how slide about perhaps as for just can data. human the saw impressive studies it you when the we we curious be

Mike Sherman

strategic to subsequent be move that. Yes we'll profile, data quickly perhaps think next and granularity move safety is that you that. on of in may think for given some to attractive looking our bit a that humans a actually The more just the been how data call. ongoing. fresh defer all able at give I I until and we'd we I call will development one that say pretty in we really very course. that's that there's options But question already prior forward We're little

Ed White

Okay. question. Thanks, Mike for taking my

Mike Sherman

Ed. Thanks,

Operator

Research. Roy Our with next question comes Soumit Jones from

Soumit Roy

natural second-line study. history looking look question I If the you're are you bit progression us you everyone. to and available? the of What little on the expect the progress. at if on the disease ask wanted a you're to for to taking you doing, can you after And size congrats when study treatment. of going Hi, can be at? the elaborate should we data frontline, Thank that give

Mike Sherman

the of Part come A we – both sort can the then have of describe nature And maybe I'll to and in the and can Allen B Part study back timing.

Allen Melemed

This Sure. is Thanks. Allen.

at looking two in are separate cohorts. it We

for we're the cohort. exactly data in have that that ONCXXX at the registration is looking a first think the I the cohort mirrors we population

not in So again the essentially a blinded retrospective And it's you'd what for be but we patients in of besides We're age a with going you'd doing also a some number in expect see the registration be similar going that's of see that for duration And rate response activity review to cohort. most ONCXXX. population. looking to independent study. that analysis, expect to an just saw of to other as representative response that the we're what

better prognostic with will have As are factors the questions a size, to I'll populations of of that overall second such more in the we're specific and survival timing. of but adhered. on survival much is as sample a study, any general line the progression going be predictive it see more just small because regardless understanding review really population. variables lineage imagine could you that a disease That can cohort and there which And lot we're looking their the to the blinded which population. going back PFS can characteristics about and broader pass variables you help less a of in include a Therefore, is for doing Mike to be not to more be understand us understand larger to prognostic and

Mike Sherman

all these of programs data. is what's on engaged really and interesting and for eager has Yeah been FDA the

with two so want be the data this do data somewhat in mirror public that used may contingent we they as it's that the of XX-patient FDA generated. we we can match it for with So our possible What share we'll It's pace as which the that cohort on assess see the even the to of one that patients that criteria we we steps with essentially evaluate communications is FDA. as share go. the that cohort that that first

to on that data an So the year. here give be to – update middle would expect before of and able I the

Soumit Roy

Okay.

with talk meetings? include separate the and setting half be there conversation first national the filing the the to So frontline going trial are on talk will the two history FDA about that or NDA the

Mike Sherman

natural actually the have history had Yeah, ongoing. disease FDA we conversations -- that's and on actually is that with

So it's -- it will touch both.

Soumit Roy

be And a we that? trial? it. Could AML. progress elaborate being go-forward AML in mentioned a the Got frontline for strategy the Okay. one last your endpoint MRD is, AML Do could think you potential question on on that negative you

Mike Sherman

Yeah, recognized and yet still endpoint we've in acquired event-free we when AML durability of terms had predicting as in talked survival not before, was responses we that seen MRD sort really of endpoint survival. overall formally as or and its it it's power -- DSTAT, about both an well recognized something early data suggested isn't

trial particular hadn't cohort been the And allow to the as endpoint endpoints. as door about one left endpoint at essentially we as open run portion both early a using left overall the to unblinded. the seen would overall used as with the that company trial, I as using a the into other it used that survival and early data faster long endpoints of from us least we're trial that or provide at primary assessment ready our so some a it for were be for trial think that, then the an they've would as not you time MRD agree in of that setting. if so FDA conversations much we they to door and And to as is that additional And the open support trial. design hadn't you've They open. point they event-free primary that can that had trial and able to for And to incorporated the submission smaller yet in survival trial alternative well that this

an than it be pull to that may more that as contemplated currently as that that's smaller always lines time is can reference a time the development rapid accelerate potentially So that size endpoint trial both lever well the assessment. we as there to continues, is

Soumit Roy

you. Thank color. Great

Allen Melemed

Allen. is this Sumit,

emergency looking I approved think rate response potentially Again, meaningful be on Just yet. But -- have becoming difference to to and this, is show AML not a really has conversation continue drug at for this on based other add complete we'll need to FDA. a with more and clinically FDA research a openness to there a measures. with

Soumit Roy

color the taking appreciate Really and again right. the thanks All questions. for

Mike Sherman

you. Thank

Operator

Langford with from question Cowen. Troy next Our comes

Troy Langford

and for on I XXX I a of congrats a Hi, taking have our the follow-up thanks couple ones quick and on questions. question. progress then just have

on want? FDA significant good expect completion any the data pretty history you ONCXXX the all what think study a you you'll have quickly how do analysis or with And So you natural could alignment idea first for registrational natural the the after of file then think the you of the do they cohort, approval? of ONCXXX, history on do in need comparison from you

Mike Sherman

analysis Yeah, discussion with we'll is the that's of data kind part that what small exactly have of sets in cases. is both expected

standards what think from we of on rare. And that conclude occur data we if that do not can see care you with And to data. are as that I that that with some having they're would durable again with said, limitations there's been expect they they're -- current do responses obviously that ONCXXX.

from comes those share so as data the data. these discussions are give So the update got as time to pretty that open part continuous nice submit for are with clarification a the of be We'll here the these all we'll discussions FDA for streams. to how midyear. able doing FDA dialogue to that we're of looking on And the that's and progress at we it have ongoing that will able work been just have as be make before work and line we've

And so potential to middle by the of time NDA you be submission. able the give we'll on lines for year, guidance a

Troy Langford

just then ONCXXX? work you Great. the And any possibly you data on on quick we see us Can this still update program Okay. provide one from year? this pipeline. question Do for the think

Mike Sherman

give Maybe let on that Josh an program. can update

Josh Allen

Sure.

brain tumors. sponsored escalation recurrent reminder tumors. on trials One So quick just study as NIH is a is focused advanced proceeding really in at currently ONCXXX two in a the CNS oncology adult dose through conducted both

The of really and dose that proceeding emerges freeing based the this lines other come. they the nature recently clinical Both maximum in and time tumors tolerated to proceeding of that setting. clinical brain Due then of as expansion pediatric both hold cohorts remains of experience promise effectively efficiently be study is those are for the up until studies. the dose on and the drug on tumor other the a at trial where dependent outcomes those into launched is to in gained more data

to continue those So dose at expect we this point studies escalation.

get guided be share data. we're the that that to that continuing end the once of out expected. we we we'll be that And But course able assume in we've in past the year. meantime just could as to think I in would that along escalation to expect of the the play you throughout dose

Troy Langford

Thanks. great. Okay,

Allen Melemed

not just we're continuing which not Allen. We're also at but evaluate we've guidance just ONCXXX, to is this stopping that Troy, we're on And given is -- one pronounced

Troy Langford

Okay. That's lot all really Thanks for helpful. a the color.

Operator

That back for call concludes Mike today's Sherman question-and-answer closing session. remarks. turn I'd the to like to

Mike Sherman

the forward morning. Great. good coming Have again update you a months. this day. in Look Thanks continuing to for your to everyone time

Operator

This concludes call. Thank for participating. conference today’s you

may disconnect. now You

Chimerix (CMRX) 1 Mar 222021 Q4 Earnings call transcript